Ultragenyx Pharmaceutical (NASDAQ:RARE) Releases Quarterly Earnings Results, Misses Expectations By $0.07 EPS

Ultragenyx Pharmaceutical (NASDAQ:RARE) announced its earnings results on Thursday. The biopharmaceutical company reported ($1.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.32) by ($0.07), Zacks reports. Ultragenyx Pharmaceutical had a negative net margin of 106.93% and a negative return on equity of 187.12%.

Ultragenyx Pharmaceutical Stock Performance

Shares of NASDAQ:RARE traded up $0.09 during trading on Thursday, reaching $43.52. 783,997 shares of the stock traded hands, compared to its average volume of 887,558. Ultragenyx Pharmaceutical has a 52-week low of $37.02 and a 52-week high of $60.37. The stock has a market cap of $4.02 billion, a P/E ratio of -6.73 and a beta of 0.60. The stock has a 50-day moving average of $43.81 and a two-hundred day moving average of $49.59.

Analysts Set New Price Targets

Several analysts have weighed in on the company. Canaccord Genuity Group reaffirmed a “buy” rating and set a $121.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, November 12th. Cantor Fitzgerald restated an “overweight” rating and set a $118.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, January 22nd. TD Cowen upped their price target on Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. Wedbush reissued a “neutral” rating and set a $48.00 price objective (up previously from $46.00) on shares of Ultragenyx Pharmaceutical in a research report on Monday, January 13th. Finally, Wells Fargo & Company upped their target price on shares of Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the stock an “overweight” rating in a research report on Friday, December 20th. One research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $92.43.

Insider Activity at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 11,727 shares of the business’s stock in a transaction dated Monday, December 30th. The stock was sold at an average price of $42.23, for a total value of $495,231.21. Following the completion of the transaction, the chief executive officer now owns 2,183,985 shares of the company’s stock, valued at approximately $92,229,686.55. The trade was a 0.53 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 5.80% of the stock is currently owned by insiders.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.